- NYSE:PFE gained 1.11% during Friday’s trading session.
- The UK approves Paxlovid for use in high-risk adults.
- South Africa sees a steep drop-off in the Omicron variant.
NYSE:PFE managed to close another calendar year on a high note, as the latest COVID-19 variant continues to spread rapidly across the US. Shares of Pfizer gained 1.11% on Friday and closed the trading session at $59.05. Pfizer is now up 60% during the year, which has handily outperformed the benchmark S&P 500 which gained 26.89% in 2021. In fact, all three major indices closed the year in positive territory for the third consecutive year, as the US markets continue to shrug off the persistent presence of the COVID-19 pandemic.
Stay up to speed with hot stocks' news!
On Friday, the UK officially approved Pfizer’s latest COVID-19 treatment, the antiviral pill called Paxlovid. The UK has been one of the countries that has been hit by the Omicron variant as it continues to break new case records with each passing day. Paxlovid has been approved for adults over the age of 18 with mild to moderate symptoms, but who also have underlying conditions that put them at high risk for more serious infection. Paxlovid has been shown to reduce hospitalizations by 90% when taken early on in the infection and has been much more effective than rival Merck’s antiviral pill which the UK approved last month.
Pfizer stock forecast
In some positive news, South Africa is reporting a steep decline in cases of the Omicron variant suggesting that the worst is now over. The country has lifted its curfew for New Year’s celebrations, which may be good news for other countries including the US. Timelines have generally been accurate in how COVID-19 behaves in one country to another, so we could very well be seeing the peak of the Omicron variant over the next couple of weeks.
Like this article? Help us with some feedback by answering this survey:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD climbs to 10-day highs above 1.0700
EUR/USD gained traction and rose to its highest level in over a week above 1.0700 in the American session on Tuesday. The renewed US Dollar weakness following the disappointing PMI data helps the pair stretch higher.
GBP/USD extends recovery beyond 1.2400 on broad USD weakness
GBP/USD gathered bullish momentum and extended its daily rebound toward 1.2450 in the second half of the day. The US Dollar came under heavy selling pressure after weaker-than-forecast PMI data and fueled the pair's rally.
Gold struggles around $2,325 despite broad US Dollar’s weakness
Gold reversed its direction and rose to the $2,320 area, erasing a large portion of its daily losses in the process. The benchmark 10-year US Treasury bond yield stays in the red below 4.6% following the weak US PMI data and supports XAU/USD.
Here’s why Ondo price hit new ATH amid bearish market outlook Premium
Ondo price shows no signs of slowing down after setting up an all-time high (ATH) at $1.05 on March 31. This development is likely to be followed by a correction and ATH but not necessarily in that order.
Germany’s economic come back
Germany is the sick man of Europe no more. Thanks to its service sector, it now appears that it will exit recession, and the economic future could be bright. The PMI data for April surprised on the upside for Germany, led by the service sector.